Noninvasive cancer biomarkers are the alternatives for the invasive tissue biopsies used for the detection of tumor presence in various cancer types. These biomarkers are used for detecting the state of disease. There are various types of biomarkers available such as circulation tumor DNA, serum micro RNAs, DNA methylation based biomarker, and protein based biomarkers and others.
Due to the COVID-19 pandemic, the global Noninvasive Cancer Biomarkers market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2023-2030. Fully considering the economic change by this health crisis, the Europe Noninvasive Cancer Biomarkers market is estimated at US$ million in 2023, while the United States and China are forecast to reach US$ million and US$ million by 2030, respectively. The proportion of the United States is % in 2023, while Chinese percentage is %, and it is predicted that China market share will reach % in 2030, trailing a CAGR of % through the analysis period. As for the Europe Noninvasive Cancer Biomarkers landscape, Germany is projected to reach US$ million by 2030. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Increased cancer occurrence rate and development in the diagnosis and treatment is creating the market for noninvasive cancer biomarkers. Moreover, increased funding by various government as well as non-government organization in the oncology segment also supports the overall market. Availability of large number of kits in the market and the marketing strategies used by various manufacturers is creating competitive environment for the noninvasive cancer biomarkers market. Continuous research in this field also deepens the molecular understanding of cancer which increases the availability of biomarkers in the market.
This report focuses on Noninvasive Cancer Biomarkers volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Noninvasive Cancer Biomarkers market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Noninvasive Cancer Biomarkers Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Protein Based Biomarkers
DNA Based Biomarkers
MRNA Based Biomarkers
Micro RNA Based Biomarkers
Segment by Application
Hospitals
Clinics
Diagnostic Laboratories
Academic and Research Institutes
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Abbott
Bio-Rad
Merck
Roche
Sino Biological
Thermo Fisher Scientific
